Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2284) 2284
Book Review (591) 591
Publication (285) 285
Book Chapter (13) 13
Conference Proceeding (5) 5
Magazine Article (2) 2
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1994) 1994
humans (1803) 1803
antifungal agents - therapeutic use (1517) 1517
echinocandins (1039) 1039
echinocandins - therapeutic use (943) 943
lipopeptides (918) 918
male (823) 823
microbiology (761) 761
pharmacology & pharmacy (740) 740
female (706) 706
caspofungin (678) 678
infectious diseases (660) 660
antifungal agents - pharmacology (633) 633
candidiasis - drug therapy (577) 577
middle aged (518) 518
voriconazole (491) 491
adult (485) 485
amphotericin-b (472) 472
antifungal agents (455) 455
fluconazole (438) 438
micafungin (434) 434
treatment outcome (407) 407
microbial sensitivity tests (405) 405
animals (400) 400
aged (395) 395
amphotericin b - therapeutic use (392) 392
echinocandins - pharmacology (392) 392
mycoses - drug therapy (383) 383
antifungal agents - administration & dosage (353) 353
peptides, cyclic - therapeutic use (349) 349
candidiasis (326) 326
triazoles - therapeutic use (317) 317
aspergillosis - drug therapy (316) 316
drug therapy, combination (312) 312
echinocandin (307) 307
candida - drug effects (306) 306
invasive candidiasis (289) 289
liposomal amphotericin-b (285) 285
lipopeptides - therapeutic use (282) 282
mycoses (281) 281
aspergillosis (280) 280
candidiasis - microbiology (274) 274
antifungal agents - adverse effects (268) 268
amphotericin b (266) 266
echinocandins - administration & dosage (261) 261
drug resistance, fungal (260) 260
mycology (256) 256
candida (255) 255
fungal-infections (251) 251
infections (248) 248
epidemiology (243) 243
health aspects (239) 239
antifungal agents - pharmacokinetics (234) 234
pyrimidines - therapeutic use (224) 224
therapy (224) 224
pharmacokinetics (222) 222
anidulafungin (221) 221
candidemia (212) 212
adolescent (210) 210
immunology (208) 208
drug therapy (202) 202
fluconazole - therapeutic use (202) 202
mortality (201) 201
mice (200) 200
bacterial infections and mycoses (199) 199
child (195) 195
fungal infections (195) 195
invasive fungal-infections (188) 188
immunocompromised host (186) 186
fungi (185) 185
echinocandins - adverse effects (183) 183
susceptibility (178) 178
risk factors (171) 171
care and treatment (167) 167
invasive aspergillosis (167) 167
infection (166) 166
candida - isolation & purification (163) 163
retrospective studies (162) 162
antifungal therapy (160) 160
candida albicans - drug effects (159) 159
transplantation (159) 159
echinocandins - pharmacokinetics (151) 151
aged, 80 and over (150) 150
efficacy (150) 150
young adult (150) 150
analysis (148) 148
in-vitro (148) 148
internal medicine (148) 148
amphotericin b - pharmacology (145) 145
blood-stream infections (145) 145
peptides, cyclic (143) 143
research (141) 141
azoles (140) 140
antifungal (138) 138
antifungals (137) 137
in-vitro activity (133) 133
aspergillus (132) 132
itraconazole (132) 132
medicine & public health (132) 132
amphotericin b - administration & dosage (130) 130
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2108) 2108
Spanish (80) 80
Japanese (31) 31
French (26) 26
German (24) 24
Chinese (12) 12
Turkish (5) 5
Russian (4) 4
Dutch (2) 2
Portuguese (2) 2
Danish (1) 1
Italian (1) 1
Norwegian (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America
by Patterson, Thomas F and Thompson, George R and Denning, David W and Fishman, Jay A and Hadley, Susan and Herbrecht, Raoul and Kontoyiannis, Dimitrios P and Marr, Kieren A and Morrison, Vicki A and Nguyen, M. Hong and Segal, Brahm H and Steinbach, William J and Stevens, David A and Walsh, Thomas J and Wingard, John R and Young, Jo-Anne H and Bennett, John E
Clinical Infectious Diseases, ISSN 1058-4838, 08/2016, Volume 63, Issue 4, pp. e1 - e60
It is important to realize that guidelines cannot always account for individual variation among patients. They are not intended to supplant physician judgment... 
Allergic aspergillosis | Fungal diagnostics | Azoles | Amphotericin | Aspergillosis | Chronic aspergillosis | Echniocandins | Invasive aspergillosis | BRONCHOALVEOLAR LAVAGE FLUID | INFECTIOUS DISEASES | fungal diagnostics | CHRONIC PULMONARY ASPERGILLOSIS | EMPIRICAL ANTIFUNGAL THERAPY | MICROBIOLOGY | echniocandins | INVASIVE FUNGAL-INFECTIONS | IMMUNOLOGY | BETA-D-GLUCAN | LIPOSOMAL AMPHOTERICIN-B | CELL TRANSPLANT RECIPIENTS | amphotericin | invasive aspergillosis | azoles | aspergillosis | chronic aspergillosis | ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS | CENTRAL-NERVOUS-SYSTEM | allergic aspergillosis | PRIMARY CUTANEOUS ASPERGILLOSIS | Infectious Disease Medicine - organization & administration | Societies, Medical | United States | Humans | Echinocandins - therapeutic use | Aspergillosis - diagnosis | Azoles - therapeutic use | Amphotericin B - therapeutic use | Aspergillosis - epidemiology | Antifungal Agents - therapeutic use | Aspergillosis - drug therapy | Care and treatment | Amphotericin B | Analysis | Practice guidelines (Medicine) | Dosage and administration | Diagnosis | Index Medicus | Idsa Guideline | Medical Guideline
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text In Vitro Susceptibilities of 217 Clinical Isolates of Zygomycetes to Conventional and New Antifungal Agents
by Nikolaos G. Almyroudis and Deanna A. Sutton and Annette W. Fothergill and Michael G. Rinaldi and Shimon Kusne
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 07/2007, Volume 51, Issue 7, pp. 2587 - 2590
Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit... 
VORICONAZOLE | CASPOFUNGIN | POSACONAZOLE | CARE CANCER CENTER | SALVAGE THERAPY | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | DISSEMINATED ZYGOMYCOSIS | AMPHOTERICIN-B | ASPERGILLUS SPP | ITRACONAZOLE | FILAMENTOUS FUNGI | Humans | Fluconazole - therapeutic use | Antifungal Agents - therapeutic use | Itraconazole - therapeutic use | Microbial Sensitivity Tests | Ketoconazole - therapeutic use | Pyrimidines - therapeutic use | Flucytosine - therapeutic use | Caspofungin | Voriconazole | Echinocandins | Peptides, Cyclic - therapeutic use | Amphotericin B - therapeutic use | In Vitro Techniques | Mucormycosis - drug therapy | Lipopeptides | Triazoles - therapeutic use | Index Medicus | Susceptibility
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Executive summary: Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America
by Patterson, Thomas F and Thompson, George R and Denning, David W and Fishman, Jay A and Hadley, Susan and Herbrecht, Raoul and Kontoyiannis, Dimitrios P and Marr, Kieren A and Morrison, Vicki A and Nguyen, M. Hong and Segal, Brahm H and Steinbach, William J and Stevens, David A and Walsh, Thomas J and Wingard, John R and Young, Jo-Anne H and Bennett, John E
Clinical Infectious Diseases, ISSN 1058-4838, 08/2016, Volume 63, Issue 4, pp. 433 - 442
It is important to realize that guidelines cannot always account for individual variation among patients. They are not intended to supplant physician judgment... 
Allergic aspergillosis | Fungal diagnostics | Azoles | Amphotericin | Aspergillosis | Chronic aspergillosis | Echniocandins | Invasive aspergillosis | Infectious Disease Medicine - organization & administration | Societies, Medical | Practice Guidelines as Topic - standards | United States | Humans | Echinocandins - therapeutic use | Aspergillosis - diagnosis | Azoles - therapeutic use | Amphotericin B - therapeutic use | Aspergillosis - epidemiology | Antifungal Agents - therapeutic use | Aspergillosis - drug therapy | Bacteria | Infectious diseases | Physicians | Judgment | Index Medicus | Idsa Guideline | amphotericin | invasive aspergillosis | fungal diagnostics | azoles | aspergillosis | chronic aspergillosis | allergic aspergillosis | echniocandins
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 Update
by Maertens, J and Marchetti, O and Herbrecht, R and Cornely, OA and Fluckiger, U and Frere, P and Gachot, B and Heinz, WJ and Lass-Florl, C and Ribaud, P and Thiebaut, A and Cordonnier, C and Third European Conference Infect L and Third European Conference on Infections in Leukemia and on behalf of the third European Conference on Infections in Leukemia
Bone Marrow Transplantation, ISSN 0268-3369, 05/2011, Volume 46, Issue 5, pp. 709 - 718
In 2005, several groups, including the European Group for Blood and Marrow Transplantation, the European Organization for Treatment and Research of Cancer, the... 
leukemia | SCT | FLUCONAZOLE PROPHYLAXIS | neutropenia | NEUTROPENIC PATIENTS | antifungals | IMMUNOLOGY | PERSISTENT FEVER | LIPOSOMAL AMPHOTERICIN-B | TRANSPLANTATION | CLINICAL-PRACTICE GUIDELINES | Aspergillus | ONCOLOGY | DOUBLE-BLIND TRIAL | Candida | HIGH-RISK | INVASIVE FUNGAL-INFECTION | PLACEBO-CONTROLLED TRIAL | MARROW-TRANSPLANTATION | HEMATOLOGY | Mycoses - prevention & control | Lipopeptides - therapeutic use | Humans | Hematopoietic Stem Cell Transplantation | Leukemia - drug therapy | Opportunistic Infections - prevention & control | Neutropenia - drug therapy | Antifungal Agents - therapeutic use | Candidiasis - drug therapy | Pyrimidines - therapeutic use | Mycoses - drug therapy | Voriconazole | Echinocandins - therapeutic use | Immunocompromised Host | Aspergillosis - drug therapy | Triazoles - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Molecular Identification and Antifungal Susceptibility of Yeast Isolates Causing Fungemia Collected in a Population-Based Study in Spain in 2010 and 2011
by Jesús Guinea and Óscar Zaragoza and Pilar Escribano and Estrella Martín-Mazuelos and Javier Pemán and Ferrán Sánchez-Reus and Manuel Cuenca-Estrella and GEIH-GEMICOMED SEIMC and REIPI and CANDIPOP Project and CANDIPOP Project, GEIH-GEMICOMED (SEIMC), and REIPI
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 03/2014, Volume 58, Issue 3, pp. 1529 - 1537
Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit... 
SPECIES DISTRIBUTION | SPP | INFECTIONS | MULTICENTER | CANDIDA-ALBICANS | ECHINOCANDIN | SURVEILLANCE | RESISTANCE | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | CASPOFUNGIN MICS | EPIDEMIOLOGY | Humans | Candidiasis - epidemiology | Candida tropicalis - drug effects | Candidiasis - microbiology | Fungemia - microbiology | Antifungal Agents - therapeutic use | Itraconazole - therapeutic use | Microbial Sensitivity Tests | Ketoconazole - therapeutic use | Candida albicans - drug effects | Candidiasis - drug therapy | Fungemia - drug therapy | Pyrimidines - therapeutic use | Spain - epidemiology | Voriconazole | Echinocandins - therapeutic use | Candida - drug effects | Fungemia - epidemiology | Drug Resistance, Fungal | Candida glabrata - drug effects | Triazoles - therapeutic use | Index Medicus | Epidemiology and Surveillance
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Prevalent mutator genotype identified in fungal pathogen Candida glabrata promotes multi-drug resistance
by Healey, Kelley R and Zhao, Yanan and Perez, Winder B and Lockhart, Shawn R and Sobel, Jack D and Farmakiotis, Dimitrios and Kontoyiannis, Dimitrios P and Sanglard, Dominique and Taj-Aldeen, Saad J and Alexander, Barbara D and Jimenez-Ortigosa, Cristina and Shor, Erika and Perlin, David S
Nature Communications, ISSN 2041-1723, 03/2016, Volume 7, Issue 1, pp. 11128 - 11128
The fungal pathogen Candida glabrata has emerged as a major health threat since it readily acquires resistance to multiple drug classes, including triazoles... 
PROPHYLAXIS | ANTIFUNGAL DRUG-RESISTANCE | REDUCED SUSCEPTIBILITY | MICAFUNGIN | MULTIDISCIPLINARY SCIENCES | AMPHOTERICIN-B | FKS MUTATIONS | CLINICAL ISOLATE | EPIDEMIOLOGY | ECHINOCANDIN RESISTANCE | ERG6 GENE | Kidney - pathology | Drug Resistance, Multiple - drug effects | Humans | Colony Count, Microbial | Candidiasis - microbiology | Antifungal Agents - therapeutic use | Candidiasis - drug therapy | Gene Deletion | Genes, Fungal | Echinocandins - pharmacology | Disease Models, Animal | Antifungal Agents - pharmacology | Drug Resistance, Multiple - genetics | Kidney - drug effects | Drug Resistance, Fungal - drug effects | Genotype | Drug Resistance, Fungal - genetics | Mutation - genetics | Kidney - microbiology | Phenotype | Animals | Candida glabrata - isolation & purification | Echinocandins - therapeutic use | Mice | Candida glabrata - genetics | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Combination Therapy for Mucormycosis: Why, What, and How?
by Brad Spellberg and Ashraf Ibrahim and Emmanuel Roilides and Russel E. Lewis and Olivier Lortholary and George Petrikkos and Dimitrios P. Kontoyiannis and Thomas J. Walsh
Clinical Infectious Diseases, ISSN 1058-4838, 1/2012, Volume 54, Issue suppl_1, pp. S73 - S78
The high mortality rate of mucormycosis with currently available monotherapy, particularly in hematology patients, has stimulated interest in studying novel... 
Antifungals | Mucormycosis | Animal models | Mucorales | Polyenes | Lipids | Mice | Infections | Dosage | Zygomycosis | RHIZOPUS-ORYZAE | INFECTIOUS DISEASES | LIPID COMPLEX | MICROBIOLOGY | DISSEMINATED ZYGOMYCOSIS | NEUTROPENIC PATIENTS | IMMUNOLOGY | FILAMENTOUS FUNGI | LIPOSOMAL AMPHOTERICIN-B | CELL TRANSPLANT RECIPIENTS | IRON CHELATOR | INVASIVE FUNGAL-INFECTION | CRYPTOCOCCAL MENINGITIS | Triazoles - administration & dosage | Benzoates - therapeutic use | Humans | Treatment Outcome | Clinical Trials as Topic | Lipids - administration & dosage | Lipids - therapeutic use | Antifungal Agents - therapeutic use | Benzoates - administration & dosage | Echinocandins - administration & dosage | Polyenes - administration & dosage | Animals | Polyenes - therapeutic use | Mucormycosis - microbiology | Echinocandins - therapeutic use | Drug Therapy, Combination | Mucormycosis - drug therapy | Antifungal Agents - administration & dosage | Triazoles - therapeutic use | Clinical trials | Toxicity | Mortality | Medical treatment | Index Medicus | Supplement
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Combination antifungal therapy for invasive aspergillosis a randomized trial
by Marr, Kieren A and Schlamm, Haran T and Herbrecht, Raoul and Rottinghaus, Scott T and Bow, Eric J and Cornely, Oliver A and Heinz, Werner J and Jagannatha, Shyla and Koh, Liang Piu and Kontoyiannis, Dimitrios P and Lee, Dong-Gun and Nucci, Marcio and Pappas, Peter G and Slavin, Monica A and Queiroz-Telles, Flavio and Selleslag, Dominik and Walsh, Thomas J and Wingard, John R and Maertens, Johan A
Annals of Internal Medicine, ISSN 0003-4819, 01/2015, Volume 162, Issue 2, pp. 81 - 89
Background: Invasive aspergillosis (IA) is associated with poor outcomes in patients with hematologic malignancies (HMs) and hematopoietic cell transplantation... 
CELL TRANSPLANT RECIPIENTS | VORICONAZOLE | MORTALITY | MEDICINE, GENERAL & INTERNAL | IN-VITRO | MULTICENTER | PULMONARY ASPERGILLOSIS | PHARMACOKINETICS | ANIDULAFUNGIN | GALACTOMANNAN INDEX | AMPHOTERICIN-B | Hematologic Neoplasms - therapy | Antifungal Agents - adverse effects | Humans | Middle Aged | Aspergillosis - diagnosis | Male | Antifungal Agents - therapeutic use | Young Adult | Karnofsky Performance Status | Aged, 80 and over | Aspergillosis - mortality | Adult | Female | Hematologic Neoplasms - complications | Drug Therapy, Combination | Aspergillosis - complications | Aspergillosis - drug therapy | Double-Blind Method | Voriconazole - adverse effects | Hematopoietic Stem Cell Transplantation | Voriconazole - therapeutic use | Treatment Outcome | Echinocandins - adverse effects | Platelet Count | Mannans - blood | Adolescent | Echinocandins - therapeutic use | Aged | Drug therapy, Combination | Anidulafungin | Drug therapy | Patient outcomes | Methods | Aspergillosis | Patient safety | Medical research | Blood diseases | Medical treatment | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Pharmacodynamic optimization for treatment of invasive Candida auris infection
by Lepak, Alexander J and Zhao, Miao and Berkow, Elizabeth L and Lockhart, Shawn R and Andes, David R
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 08/2017, Volume 61, Issue 8
Candida auris is an emerging multidrug-resistant threat. The pharmacodynamics of three antifungal classes against nine C. auris strains was explored using a... 
Antifungal resistance | Antifungal therapy | Pharmacodynamics | C. auris | antifungal therapy | GLABRATA | pharmacodynamics | CLONAL STRAIN | SUSCEPTIBILITY | MICROBIOLOGY | MODEL | antifungal resistance | PHARMACOLOGY & PHARMACY | FLUCONAZOLE | INDIA | NOSOCOMIAL FUNGEMIA | Lipopeptides - therapeutic use | Echinocandins - pharmacokinetics | Humans | Candidiasis - microbiology | Fluconazole - therapeutic use | Antifungal Agents - therapeutic use | Microbial Sensitivity Tests | Candidiasis - drug therapy | Antifungal Agents - pharmacokinetics | Candidiasis, Invasive - drug therapy | Echinocandins - blood | Amphotericin B - pharmacokinetics | Disease Models, Animal | Amphotericin B - blood | Lipopeptides - pharmacokinetics | Fluconazole - blood | Drug Resistance, Multiple, Fungal | Lipopeptides - blood | Candida - isolation & purification | Fluconazole - pharmacokinetics | Animals | Candida - pathogenicity | Echinocandins - therapeutic use | Mice | Candida - drug effects | Amphotericin B - therapeutic use | Candidiasis, Invasive - microbiology | Antifungal Agents - blood | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Epidemiology and Outcomes of Candidemia in 2019 Patients: Data from the Prospective Antifungal Therapy Alliance Registry
by David L. Horn and Dionissios Neofytos and Elias J. Anaissie and Jay A. Fishman and William J. Steinbach and Ali J. Olyaei and Kieren A. Marr and Michael A. Pfaller and Chi-Hsing Chang and Karen M. Webster
Clinical Infectious Diseases, ISSN 1058-4838, 6/2009, Volume 48, Issue 12, pp. 1695 - 1703
Background. Candidemia remains a major cause of morbidity and mortality in the health care setting, and the epidemiology of Candida infection is changing.... 
Antifungals | Intensive care units | Health outcomes | Infectious diseases | Mortality | Articles and Commentaries | Predisposing factors | Infections | Candidemia | Fungal infections | Epidemiology | INFECTIOUS DISEASES | RISK-FACTORS | MICROBIOLOGY | INVASIVE FUNGAL-INFECTIONS | IMMUNOLOGY | HOSPITAL-ACQUIRED CANDIDEMIA | ATTRIBUTABLE MORTALITY | CANCER-PATIENTS | INTENSIVE-CARE-UNIT | NOSOCOMIAL CANDIDEMIA | CRITICALLY-ILL PATIENTS | HEMATOLOGIC MALIGNANCIES | BLOOD-STREAM INFECTIONS | Humans | Middle Aged | Candidiasis - epidemiology | Child, Preschool | Infant | Male | Fluconazole - therapeutic use | Antifungal Agents - therapeutic use | Incidence | Young Adult | Candida - classification | Candidiasis - drug therapy | Fungemia - drug therapy | Aged, 80 and over | Adult | Female | Child | Infant, Newborn | Cross Infection - epidemiology | Treatment Outcome | Candida - isolation & purification | Cross Infection - drug therapy | Adolescent | Survival Analysis | Echinocandins - therapeutic use | Aged | Fungemia - epidemiology | Amphotericin B - therapeutic use | Candidiasis | Patient outcomes | Antifungal agents | Dosage and administration | Diagnosis | Research | Drug therapy | Health aspects | Fungi | Studies | Clinical outcomes | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights